Infliximab-induced psoriasis during therapy for Crohn's disease

dc.contributorHosp Israelita Albert Einstein
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorUniversidade de São Paulo (USP)
dc.date.accessioned2014-05-20T13:32:37Z
dc.date.available2014-05-20T13:32:37Z
dc.date.created2014-05-20T13:32:37Z
dc.date.issued2012-06-01
dc.identifierJournal of Crohns & Colitis. Amsterdam: Elsevier B.V., v. 6, n. 5, p. 610-616, 2012.
dc.identifier1873-9946
dc.identifierhttp://hdl.handle.net/11449/11130
dc.identifier10.1016/j.crohns.2011.12.007
dc.identifierWOS:000304689700016
dc.description.abstractAlthough therapy with tumor necrosis factor-alpha inhibitors (anti-TNF) provides beneficial effects in different immune inflammatory disorders, paradoxical cases of anti-THE-induced psoriasis have increasingly been reported, mostly in the setting of rheumatologic diseases. To date, less than 50 cases of infliximab-induced psoriasis in inflammatory bowel disease patients have been described. The present report was aimed at describing two new cases of infliximab-induced psoriasis during therapy for Crohn's disease and at carrying out a review on this intriguing phenomenon. (C) 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
dc.languageeng
dc.publisherElsevier B.V.
dc.relationJournal of Crohns & Colitis
dc.relation6.637
dc.relation2,728
dc.rightsAcesso restrito
dc.sourceWeb of Science
dc.subjectBiological therapy
dc.subjectCrohn's disease
dc.subjectInfliximab
dc.subjectPsoriasis
dc.subjectTumor necrosis factor-alpha inhibitors
dc.titleInfliximab-induced psoriasis during therapy for Crohn's disease
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución